Former BARDA Director Rick Bright alleged in a whistleblower complaint that other Trump administration officials wanted widespread distribution of the anti-malarial hydroxychloroquine as a potential coronavirus treatment, despite efforts by him and the FDA’s Janet Woodcock to impose limits on its use.
Bright, who was removed as head of the Biomedical Advanced Research and Development Authority on 20 April, said in the...








